Treating Posttraumatic Stress Disorder in Patients with Opioid Use Disorder

$288,694P20FY2020GMNIH

University Of Vermont & St Agric College, Burlington VT

Investigators

Linked publications, trials & patents

Paper 39109817 Paper 38580997 Paper 38488134 Paper 38300271 Paper 38181831 Paper 38131488 Paper 38079256 Paper 37977010 Paper 37820288 Paper 37820180 Paper 37755833 Paper 37602999 Paper 37532032 Paper 37527730 Paper 37499918 Paper 37303202 Paper 37284771 Paper 37261748 Paper 37249433 Paper 37227881 Paper 37023420 Paper 37019181 Paper 36989699 Paper 36857090 Paper 36845888 Paper 36822956 Paper 36812809 Paper 36808238 Paper 36745163 Paper 36710461 Paper 36692093 Paper 36595383 Paper 36581801 Paper 36576423 Paper 36515573 Paper 36355684 Paper 36334681 Paper 36272516 Paper 36252828 Paper 36208817 Paper 36152818 Paper 36048114 Paper 36044764 Paper 35995105 Paper 35995102 Paper 35937642 Paper 35870575 Paper 35805733 Paper 35787842 Paper 35771496 Paper 35605264 Paper 35587423 Paper 35560055 Paper 35533885 Paper 35474136 Paper 35389691 Paper 35343903 Paper 35283082 Paper 35267141 Paper 35248683 Paper 35157484 Paper 35136909 Paper 35108567 Paper 35093680 Paper 35074486 Paper 35073213 Paper 34990195 Paper 34866198 Paper 34850047 Paper 34840247 Paper 34840245 Paper 34822849 Paper 34817540 Paper 34797563 Paper 34748543 Paper 34682624 Paper 34665032 Paper 34626647 Paper 34599919 Paper 34561368 Paper 34461621 Paper 34461619 Paper 34411588 Paper 34358592 Paper 34347030 Paper 34302837 Paper 34291989 Paper 34290098 Paper 34259798 Paper 34255068 Paper 34242666 Paper 34224472 Paper 34158454 Paper 34119879 Trial NCT05319600 Trial NCT04693988 Trial NCT04379388 Trial NCT04104022 Trial NCT02172820 Trial NCT02052115

Abstract

Among patients with opioid use disorder (OUD), 90% report lifetime trauma exposure and 33% meet criteria for posttraumatic stress disorder (PTSD). The co-occurrence of OUD and PTSD is associated with more severe mental health symptoms and worse opioid agonist treatment (OAT) outcomes relative to either diagnosis alone. Prolonged exposure therapy (PET) is an efficacious manualized cognitive-behavioral treatment for reducing PTSD severity. Although preliminary findings indicate that PET may reduce PTSD symptom severity among patients receiving treatment for concomitant OUD, it is unclear to what extent observed improvements were a function of PET versus the psychopharmacological effects of OAT itself. Therefore, the question of whether OAT alone may attenuate PTSD symptomatology in the absence of intensive cognitive-behavioral therapy remains unanswered and is important given the prevalence and deleterious effects of PTSD among OAT patients, as well as the ever-present constraints on mental health resources in SUD treatment settings.

View original record on NIH RePORTER →